Literature DB >> 24448324

Loss of GATA3 in bladder cancer promotes cell migration and invasion.

Yi Li1, Hitoshi Ishiguro2, Takashi Kawahara2, Eiji Kashiwagi3, Koji Izumi4, Hiroshi Miyamoto2.   

Abstract

The transcription factor GATA3 is known as a breast tumor suppressor as well as a urothelial marker, and its loss is often seen in high-grade invasive bladder cancer. Nonetheless, GATA3 functions in bladder cancer cells remain largely unknown. In this study, we assessed the effects of GATA3 silencing via RNA interference on cell migration, invasion, and proliferation of bladder cancer. GATA3 expression was downregulated in all four bladder cancer lines examined, compared with a non-neoplastic urothelial line SVHUC. Knockdown of GATA3 in the bladder cancer lines (5637, TCC-SUP, J82) resulted in promotion of cell migration and invasion as well as increases in the expression of their related molecules, such as vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9, and the activity of MMP-2 and MMP-9. GATA3 loss was also associated with an increasing level of a mesenchymal marker N-cadherin and a decreasing level of an epithelial marker β-catenin. Consistent with these findings, enforced expression of GATA3 in UMUC3 inhibited cell migration and invasion. However, GATA3 showed marginal effects on bladder cancer cell viability and the expression of cell cycle- or apoptosis-related molecules. Additionally, in contrast to bladder cancer lines, no significant effects of GATA3 silencing on cell migration were seen in SVHUC. These findings suggest that GATA3 plays an important role in the prevention of bladder cancer progression and metastasis by inhibiting cell migration and invasion as well as epithelial-to-mesenchymal transition.

Entities:  

Keywords:  GATA3; bladder cancer; cell invasion; cell migration; cell proliferation

Mesh:

Substances:

Year:  2014        PMID: 24448324      PMCID: PMC3979820          DOI: 10.4161/cbt.27631

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  38 in total

1.  Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation.

Authors:  Marie-Liesse Asselin-Labat; Kate D Sutherland; Holly Barker; Richard Thomas; Mark Shackleton; Natasha C Forrest; Lynne Hartley; Lorraine Robb; Frank G Grosveld; Jacqueline van der Wees; Geoffrey J Lindeman; Jane E Visvader
Journal:  Nat Cell Biol       Date:  2006-12-24       Impact factor: 28.824

2.  Aberrant gata-3 expression in human pancreatic cancer.

Authors:  Antanas Gulbinas; Pascal O Berberat; Zilvinas Dambrauskas; Thomas Giese; Nathalia Giese; Frank Autschbach; Joerg Kleeff; Stefan Meuer; Markus W Büchler; Helmut Friess
Journal:  J Histochem Cytochem       Date:  2005-08-08       Impact factor: 2.479

3.  GATA-3 is expressed in association with estrogen receptor in breast cancer.

Authors:  R V Hoch; D A Thompson; R J Baker; R J Weigel
Journal:  Int J Cancer       Date:  1999-04-20       Impact factor: 7.396

4.  Murine and human T-lymphocyte GATA-3 factors mediate transcription through a cis-regulatory element within the human T-cell receptor delta gene enhancer.

Authors:  L J Ko; M Yamamoto; M W Leonard; K M George; P Ting; J D Engel
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

5.  Promotion of bladder cancer development and progression by androgen receptor signals.

Authors:  Hiroshi Miyamoto; Zhiming Yang; Yei-Tsung Chen; Hitoshi Ishiguro; Hiroji Uemura; Yoshinobu Kubota; Yoji Nagashima; Yu-Jia Chang; Yueh-Chiang Hu; Meng-Yin Tsai; Shuyuan Yeh; Edward M Messing; Chawnshang Chang
Journal:  J Natl Cancer Inst       Date:  2007-04-04       Impact factor: 13.506

6.  GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.

Authors:  L Shan; X Li; L Liu; X Ding; Q Wang; Y Zheng; Y Duan; C Xuan; Y Wang; F Yang; Y Shang; L Shi
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

7.  GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland.

Authors:  Hosein Kouros-Mehr; Euan M Slorach; Mark D Sternlicht; Zena Werb
Journal:  Cell       Date:  2006-12-01       Impact factor: 41.582

8.  Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.

Authors:  John P T Higgins; Gulsah Kaygusuz; Lingli Wang; Kelli Montgomery; Veronica Mason; Shirley X Zhu; Robert J Marinelli; Joseph C Presti; Matt van de Rijn; James D Brooks
Journal:  Am J Surg Pathol       Date:  2007-05       Impact factor: 6.394

9.  GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model.

Authors:  Hosein Kouros-Mehr; Seth K Bechis; Euan M Slorach; Laurie E Littlepage; Mikala Egeblad; Andrew J Ewald; Sung-Yun Pai; I-Cheng Ho; Zena Werb
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

10.  Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway.

Authors:  Brian J Wilson; Vincent Giguère
Journal:  Mol Cancer       Date:  2008-06-04       Impact factor: 27.401

View more
  16 in total

1.  Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma.

Authors:  Yue Wang; Jinxia Zhang; Yunfan Wang; Shufang Wang; Yu Zhang; Qi Miao; Fei Gao; Huiying He
Journal:  Front Med       Date:  2019-04-24       Impact factor: 4.592

2.  GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens.

Authors:  Yi Li; Hitoshi Ishiguro; Takashi Kawahara; Yurina Miyamoto; Koji Izumi; Hiroshi Miyamoto
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

3.  Identification of crucial long non-coding RNAs and mRNAs along with related regulatory networks through microarray analysis in esophageal carcinoma.

Authors:  Yaowen Zhang; Huitao Wang; Fuyou Zhou; Anlin Hao; Ningtao Dai; Haijun Yang; Anping Zheng
Journal:  Funct Integr Genomics       Date:  2021-04-16       Impact factor: 3.410

Review 4.  Androgen Receptor Signaling in Bladder Cancer.

Authors:  Peng Li; Jinbo Chen; Hiroshi Miyamoto
Journal:  Cancers (Basel)       Date:  2017-02-22       Impact factor: 6.639

5.  Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.

Authors:  Renate Pichler; Georg Gruenbacher; Zoran Culig; Andrea Brunner; Dietmar Fuchs; Josef Fritz; Hubert Gander; Andrea Rahm; Martin Thurnher
Journal:  Cancer Immunol Immunother       Date:  2016-12-22       Impact factor: 6.968

6.  Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer.

Authors:  Tejaswi Iyyanki; Baozhen Zhang; Qixuan Wang; Ye Hou; Qiushi Jin; Jie Xu; Hongbo Yang; Tingting Liu; Xiaotao Wang; Fan Song; Yu Luan; Hironobu Yamashita; Ruby Chien; Huijue Lyu; Lijun Zhang; Lu Wang; Joshua Warrick; Jay D Raman; Joshua J Meeks; David J DeGraff; Feng Yue
Journal:  Genome Biol       Date:  2021-04-15       Impact factor: 13.583

7.  A transcription factor that promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of ovarian cancer cells and its possible mechanisms.

Authors:  Yingying Qi; Kexin Mo; Ting Zhang
Journal:  Biomed Eng Online       Date:  2021-08-16       Impact factor: 2.819

Review 8.  Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor.

Authors:  Hiroki Ide; Hiroshi Miyamoto
Journal:  Dis Markers       Date:  2015-12-07       Impact factor: 3.434

9.  Biological and Clinical Significance of GATA3 Detected from TCGA Database and FFPE Sample in Bladder Cancer Patients.

Authors:  Chenglu Wang; Shuang Yang; Lu Jin; Guangcheng Dai; Qiu Yao; Han Xiang; Yongsheng Zhang; Xiaolong Liu; Boxin Xue
Journal:  Onco Targets Ther       Date:  2020-01-31       Impact factor: 4.147

10.  Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling.

Authors:  Chaozhi Tang; Jiakang Ma; Xiuli Liu; Zhengchun Liu
Journal:  Stem Cell Res Ther       Date:  2020-10-28       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.